Dr. Chari on Impact of CAR T Cells in Myeloma

Video

Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses the impact of CAR T-cell therapy in myeloma.

Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses the impact of chimeric antigen receptor (CAR) T-cell therapy in patients with myeloma.

Recent data with CAR T cells have been very encouraging, particularly with the phase I trial of bb2121 that was presented at the 2018 ASCO Annual Meeting. In a penta-refractory patient population, median progression-free survival was almost 1 year and overall response rate was 96%. Chari says this is important because these results are being seen with just 1 intervention of CAR T, unlike other treatment strategies that continue over an extended period of time.

Something to keep in mind about CAR T-cell therapy is the toxicity, especially cytokine release syndrome. It is also difficult to compare outcomes with other off-the-shelf treatment options because there is selection bias with patients who enroll for CAR T cells. Other unanswered questions with this treatment are shortening manufacturing time, getting larger patient populations enrolled, and if this therapy can be combined with other treatment.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.